# Adjuvant Toripalimab Plus Chemotherapy for EGFR/ALK Mutation Negative Stage II-IIIB(N2) NSCLC (LungMate-008)

Source: https://onco.cc/trials/nct04772287/  
OnCo record `nct04772287` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of toripalimab in lung cancer, run by Shanghai Pulmonary Hospital, Shanghai, China, not yet recruiting.

## Summary

Adjuvant Toripalimab Plus Chemotherapy for EGFR/ALK Mutation Negative Stage II-IIIB(N2) NSCLC (LungMate-008) is a phase 3, randomised interventional study registered as NCT04772287 by Shanghai Pulmonary Hospital, Shanghai, China, with a registry enrolment figure of 341 participants, started 2021-03-31 and due to reach its primary completion in 2026-12-30. Interventions recorded: Toripalimab; Toripalimab mimetic (placebo). Conditions listed: Non Small Cell Lung Cancer. Primary outcome: Disease-free survival (DFS). Lung eligibility wording from the registry: "Histological diagnosis of primary non-small cell lung cancer (NSCLC)". No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-25
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT04772287
- Phase: 3
- Setting: Adjuvant Toripalimab Versus Placebo Combined With Chemotherapy for EGFR/ALK Mutation Negative Stage II-IIIB(N2) Non-small-cell Lung Cancer (LungMate-008): a Randomised, Double-blind, Controlled, Phase 3 Trial
- Sponsor: Shanghai Pulmonary Hospital, Shanghai, China
- Enrolled: 341

## Sources

- ClinicalTrials.gov NCT04772287: https://clinicaltrials.gov/study/NCT04772287

## Connected records

- cancers: [ALK-positive non-small-cell lung cancer](https://onco.cc/cancers/alk-positive-nsclc/), [EGFR-mutated non-small-cell lung cancer](https://onco.cc/cancers/egfr-mutant-nsclc/), [Resectable stage I to III non-small-cell lung cancer](https://onco.cc/cancers/resectable-nsclc/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- drugs: [Toripalimab](https://onco.cc/drugs/toripalimab/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct04772287.json